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Background: Pulmonary hypertension (PH), a disease which carries substantial morbidity 
and mortality, has been reported to occur in 25%–45% of dialysis patients. No prospective 
  evaluation of the prevalence or clinical significance of PH in chronic dialysis patients in the 
United States (US) has been undertaken.
Methods: Echocardiograms were performed prospectively in chronic hemodialysis patients 
prior to dialysis at a single dialysis center. PH was defined as a tricuspid regurgitant jet $2.5 m/s 
and “more severe PH” as $3.0 m/s. Clinical outcomes recovered were all-cause hospitalizations 
and death at 12 months.
Results: In a cohort of 90 patients, 42 patients (47%) met the definition of PH. Of those, 
18 patients (20%) met the definition of more severe PH. At 12 months, mortality was   significantly 
higher in patients with PH (26%) compared with patients without PH (6%).   All-cause 
  hospitalizations were similar in patients with PH and without PH. Echocardiographic findings 
  suggesting impaired left ventricular function and elevated pulmonary capillary wedge pressure 
were significantly associated with PH.
Conclusion: This prospective cross-sectional study of a single dialysis unit suggests that 
PH may be present in nearly half of US dialysis patients and when present is associated with 
increased mortality. Echocardiographic findings demonstrate an association between elevated 
filling pressures, elevated pulmonary artery pressures, and higher mortality, suggesting that the 
PH may be secondary to diastolic dysfunction and compounded by volume overload.
Keywords: renal failure, pulmonary hypertension, diastolic dysfunction
Background
Pulmonary hypertension (PH) regardless of etiology has been associated with increased 
morbidity and mortality. In patients with end-stage renal disease (ESRD) requiring 
chronic hemodialysis (HD) retrospective record reviews of largely non-US popula-
tions suggest that PH occurs in about 25%–45% of patients.1–3 Various mechanisms 
have been postulated for its development, including disturbances in endothelial and 
vascular smooth muscle function,4,5 high output state3,6 related to grafts and fistulas, 
microbubble pulmonary emboli7 and pre-existing or acquired left-sided cardiac dys-
function.3,8 It is estimated that there are about 350,000 people receiving chronic HD in 
the US.9 The US dialysis patient demographic differs substantially from other reported 
populations with theoretically different prevalence and outcome of PH. Despite the 
potential burden of pulmonary hypertension in this large population, prospective data International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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regarding the prevalence of PH, clinical determinants, and 
prognostic significance is limited. Thus, the purpose of this 
study was to prospectively determine the prevalence of PH 
by echocardiography in dialysis patients in a single dialysis 
center in the US and identify the clinical significance of PH 
on all-cause mortality and morbidity.
Methods
We prospectively performed predialysis echocardiograms 
on all patients routinely attending a single dialysis center. 
Echocardiograms were performed predialysis as opposed 
to post dialysis as it was felt that the predialysis status of 
the patient more closely reflects the chronic volume status 
of the patient than the immediate post dialysis “dry weight” 
state. Baseline demographics were collected through review 
of the medical records. It was attempted to consent, enroll, 
and recover data on all the patients in this dialysis unit. All 
aspects of this study were approved by the Baylor institutional 
review board, Fresenius (the dialysis unit operator), and the 
medical director(s) of the dialysis unit.
echocardiograms and estimation  
of pulmonary hypertension
Complete echocardiograms (2-dimensional, M-Mode, and 
Doppler studies) were performed (using the Biosound 
  system), digitally stored and analyzed. Standard 2D echocar-
diographic parameters of cardiac structure and function, 
Doppler assessment of pulmonary veins, mitral inflow, 
tricuspid inflow, left ventricular outflow tract, as well as 
tissue Doppler imaging at the mitral and tricuspid annulus 
were acquired with the patient in the left lateral position 
according to recommendations from the American Society 
of Echocardiography.10–13 All echocardiograms were analyzed 
by a single reader, who was aware that all patients were 
dialysis-dependent patients but was blinded to additional 
clinical and outcomes data.
Previous studies calculated pulmonary artery systolic 
pressure (PAP) echocardiographically using the Bernoulli 
equation: PAP = 4 × (peak tricuspid regurgitant (TR) jet 
velocity)2 + 10 mmHg (estimated right atrial pressure 
(RAP)). As the RAP estimate is yet another estimate, to 
maximize the integrity of the data, PH was defined by the 
TR jet only. Thus, in the present study, PH was defined as 
a TR jet $2.5 m/s (this would be approximately equivalent 
to PAP $35 mmHg assuming a RAP of 10 mmHg); ‘more 
severe PH’ as TR jet $3.0 m/s. This methodology would 
underestimate PAP compared with prior studies but would 
more strictly define patients with PH. Patients with   insufficient 
TR jet who had echo-Doppler characteristics similar to those 
with normal TR jet velocity and no indirect echo-Doppler evi-
dence of PH (37 patients), were grouped with patients without 
PH (11 patients). Patients were divided into 3 groups based 
on peak TR jet velocity: group 1, no TR and TR ,2.5 m/s; 
group 2, TR 2.5–3.0 m/s; group 3, TR .3.0 m/s.
clinical outcomes
Data on all-cause hospitalizations and death at 4, 8, and 
12 months post echocardiogram was collected. For hospital-
ization data, complete follow up was available in 76 patients. 
For the survival analysis, all 90 patients were accounted for 
either through chart review or the United States Renal Data 
System database. The research nurse recording outcomes 
data was blinded to the results of the echo data.
statistical analysis
Differences across the 3 groups were examined using 
ANOVA for continuous variables and the Chi-square test 
for categorical variables. Variables that were not normally 
distributed were examined using non-parametric tests. The 
data are presented as mean and standard deviation unless 
otherwise specified.
For survival analysis, Kaplan Meier survival curves were 
generated, and a log rank test was used to assess for statisti-
cally significant differences between the groups.
Results
Of 133 patients attending the dialysis clinic, 103 consented to 
participation between May 2006 and May 2007. 10 patients 
relocated prior to completion of the echocardiogram, and 
3 patients were excluded due to technically inadequate 
echocardiograms. Thus, the cohort consisted of 90 consecu-
tively consented and enrolled patients.
clinical characteristics
The baseline characteristics of the patients are shown in 
Table 1. The majority of patients were male (66%), with 
an average age of 58 ± 15 years. 64% of the patients were 
African American, 18% were Hispanic, and 18%   Caucasian. 
The most frequent cause of ESRD requiring HD was a 
combination of diabetes and hypertension (33%) followed 
by hypertension alone (30%), other causes (28%), and 
lastly diabetes alone (9%). For HD access, the majority of 
patients had arteriovenous grafts (AVGs) (44%) followed by 
arteriovenous fistulas (AVFs) (40%) and catheters (16%). 
The average time on HD at the time of echocardiogram was 
3.7 ± 2.8 years.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Pulmonary hypertension
42 patients (47%) met the definition of PH of whom 
18 patients (20%) had more severe PH. Patients with PH 
were older, and there was a trend for a female predominance 
in those with more severe PH; however, this did not reach 
statistical significance (Table 1). Between the 3 groups, no 
significant differences were noted in the distribution of dif-
ferent ethnicities, type of access, years on HD, incidence of 
diabetes, hypertension, or history of coronary artery disease. 
Patients with PH did have a significantly lower body mass 
index (BMI) (P , 0.02). Laboratory parameters such as 
haptoglobin, hemoglobin and LDH (potential indicators 
of hemolysis) were not significantly different between the 
3 groups (data not shown).
Echocardiographic parameters are demonstrated in 
Table 2. As expected, patients with PH had larger right 
atrial (RA) and right ventricular (RV) sizes, higher RAP 
and a trend towards decreased RV function. Left ventricular 
(LV) size did not change with increasing TR jet velocity; 
however, a trend towards more LV hypertrophy was noted. 
The mean LV ejection fraction (LVEF) in all patients was 
58.4% ± 11% (range 22%–70%). With increasing TR jet 
velocity, a significant decrease in LV systolic function was 
noted. However, even in patients with TR $3 m/s, mean 
LVEF was preserved at 53.2% ± 14.7%. Patients with 
PH had significantly higher estimates of left sided filling 
pressures. Consistent with these findings, there was a trend 
towards larger left atrial size with increasing PAP (Table 2). 
A pericardial effusion was more frequently present in 
patients with higher PAP (0% in group 1, 8% in group 2, 
and 33% in group 3). The occurrence of significant valvular 
disease was rare in all groups.
Echocardiographic data were available for the calcu-
lation of pulmonary capillary wedge pressure (PCWP) 
in 70 patients. Patients with PH had significantly higher 
PCWP (Table 2). Correlation analysis revealed a significant 
correlation between PAP and PCWP (Pearson correlation 
coefficient = 0.5, P = 0.001).
clinical outcome
At 12 months, a total of 14 deaths (15.6%) had occurred. 
Mortality was significantly higher in patients with PH (26%) 
compared with patients without PH (6%), and this was 
driven largely by increased mortality in patients with more 
significant PH (TR $ 3 m/s). By 12 months, mortality was 
44% (8/18) in group 3 versus 6% (3/48) and 12.5% (3/24) in 
groups 1 and 2, respectively (P = 0.001). The Kaplan Meier 
survival curves are shown in Figure 1.
In exploratory analysis comparing survivors to   
non-survivors (Table 3), there was no significant differ-
ence in age, race, gender, BMI, access type, and incidence 
of diabetes or hypertension, or history of coronary artery 
disease between the 2 groups. However, patients who 
died had been on HD for a significantly longer duration 
than survivors. In addition, patients who died had larger 
RA and RV sizes, worse RV function, more severe TR, 
Table 2 echocardiographic parameters
TR velocity ,2.5 m/s 
n = 48
2.5–3.0 m/s 
n = 24
.3.0 m/s 
n = 18
P-value
Right heart echo parameters
RA volume (mL) 41.6 ± 20.3 51 ± 20.3 70.1 ± 27.9 ,0.02
RV apical 
diameter (cm)
3.5 ± 0.7 3.6 ± 0.5 4.2 ± 0.7 0.003
RV Tei 0.14 ± 0.2 0.19 ± 0.19 0.28 ± 0.17 0.053
Annular 
descent (cm)
1.9 ± 0.6 1.8 ± 0.4 1.6 ± 0.7 0.29
RV fractional 
shortening
40.8 ± 6.3 41 ± 8.7 35.4 ± 9.5 0.1
RAP (mmhg) 7.4 ± 3.4 9.6 ± 4.1 12.8 ± 4.6 ,0.02
Left heart echo parameters
LVID (cm) 4.5 ± 0.7 4.7 ± 0.6 4.6 ± 0.7 0.534
LVeF (%) 61.1 ± 7.4 56.9 ± 11.2 53.2 ± 14.7 0.017
LA volume (mL) 60.7 ± 22.1 62.5 ± 19.4 74.8 ± 26.5 0.085
PcWP (mmhg) 15.6 ± 5.3 19.5 ± 7.7 24.9 ± 7.9 ,0.02
LVha (cm) 1.4 ± 0.6 1.5 ± 0.6 1.9 ± 0.6 0.1
Note:  aaverage  wall  thickness  of  interventricular  septum  and  posterior  wall 
measured in the parasternal long axis view.
Abbreviations: TR, tricuspid regurgitant; RA, right atrial; RV, right ventricular; RAP, 
right atrial pressure; LVID, left ventricular internal dimension; LVeF, left ventricular 
ejection fraction; LA, left atrial; PcWP, pulmonary capillary wedge pressure.
Table 1 Baseline clinical characteristics
All 
n = 90
,2.5 m/s 
n = 48
2.5–3.0 m/s  
n = 24
.3.0 m/s  
n = 18
P-value
Age  
(years)
58.3 ± 15.4 54.5 ± 14.3 62.5 ± 13.6 62.4 ± 18.3 0.05
Gender  
(% male)
59M (66%)  30M (63%)  20M (83%) 9M (50%) 0.06
ethnicity
AA 
c 
h
58 (64%) 
16 (18%) 
16 (18%)
35 (73%) 
7 (15%) 
6 (13%)
13 (54%) 
3 (13%) 
8 (33%)
10 (56%) 
6 (33%) 
2 (11%)
 
0.07
BMI 27.2 ± 6.0 29.6 ± 5.9 25.1 ± 4.3 24.0 ± 5.7 ,0.02
Dialysis access
AVF 
AVG 
ca
35 (40%) 
39 (44%) 
14 (16%)
20 (43%) 
20 (43%) 
7 (15%)
12 (52%) 
8 (35%) 
3 (13%)
3 (17%) 
11 (61%) 
4 (22%)
 
0.23
Years on  
dialysis
3.6 ± 2.9 3.8 ± 2.7 3.1 ± 2.8 3.6 ± 3.3 0.67
Abbreviations:  F,  female;  M,  male;  AA,  African  American;  c,  caucasian;  h,   
Hispanic; BMI, body mass index;  AVF, arteriovenous fistula; AVG, arteriovenous graft; 
ca, catheter.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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and significantly higher RAP and PAP. There was no sig-
nificant difference in LV size between the 2 groups, but 
non-survivors did show a trend towards lower LVEF than 
survivors. Moreover, PCWP was significantly higher in 
non-survivors (Table 3).
Discussion
Previously reported data has demonstrated that PH occurs in 
about 25%–45% of patients with ESRD on HD.1–3   However, 
these analyses were retrospective, based on pat  ients undergo-
ing echocardiography for clinical indications (preselection 
bias) and were performed in non-US countries (Table 4). 
This study is the first prospective evaluation of PH in dialy-
sis patients in the US. Our study revealed that PH is highly 
prevalent in dialysis patients (47%), with 20% of the patients 
having echocardiographic evidence of more severe PH. This 
study further demonstrates that the presence of PH is associ-
ated with a significant increase in mortality with a 12-month 
mortality of 44% in patients with more severe PH. This is 
in relation to annual mortality rates of approximately 20% 
in dialysis patients in the US.9 Not surprisingly, this study 
provides evidence that the   development of PH in dialysis 
patients may reflect the impact of chronic volume overload 
and chronically elevated left heart filling pressures.
Several mechanisms have been proposed for the develop-
ment of PH in dialysis patients, and ultimately, a combination 
of multiple factors likely contributes to its development. PH 
may evolve due to the inability of the pulmonary circulation 
to accommodate increased cardiac output (resulting from 
increased volume, anemia, arteriovenous fistula) or as a result 
of increased pulmonary vascular stiffness due to endothelial 
dysfunction (decreased nitric oxide).3,5,6 In the current study, 
neither type of access nor anemia were associated with PH. 
The only echocardiographic parameters that were signifi-
cantly associated with PH in the current study were PCWP 
and LV function. 63% of patients had echocardiographic 
evidence of elevated PCWP, and an elevated PCWP was 
associated with elevated RAP and PAP. Moreover, correla-
tion analysis revealed a significant correlation between PAP 
and PCWP, suggesting that elevated PCWP may be a major 
contributor to PAP elevation.
Although there was a significant decrease in LV function 
with increasing PAP, the mean LVEF in patients with PH was 
still preserved (mean LVEF 53.2% ± 14.7%). Similarly, in 
subjects with higher estimates of PCWP, there was only a 
trend towards decreased LVEF. These findings suggest that 
diastolic heart failure with preserved LV systolic function 
may be the mechanism for elevated filling pressures in a sig-
nificant proportion of patients. The elevated filling pressures 
in turn may contribute to the development of PH. In our study 
population, volume retention appeared to contribute more 
towards elevated filling pressures than severity of diastolic 
dysfunction. This is reflected by the observation that the 
increase in filling pressures was driven more by an increase 
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Figure 1 Kaplan Meier survival estimates based on presence, absence, and degree of 
Ph by TR jet: group 1 = no TR, and TR , 2.5 m/s; group 2 = TR 2.5–3.0 m/s; group 3 = 
TR . 3.0 m/s (P = 0.0004). At 12 months, mortality was 44% (8/18) in group 3 versus 
6% (3/48) and 12.5% (3/24) in groups 1 and 2, respectively (P = 0.001). The P = 0.0004 
is based on the time to event analysis and signifies an overall difference between the 
3 curves/groups. P = 0.001 is based on a chi-square test for the number of deaths by 
12 months between the 3 groups. 
Abbreviation: TR, tricuspid regurgitant.
Table 3 Analysis by survivors and non-survivors
Survivors 
n = 76
Non-survivors 
n = 14
P-value
Age 57.4 ± 15 62.79 ± 16.8 0.23
Race 49AA, 14c, 13h 9AA, 2c, 3h 0.89
Gender 52M, 24F 7M, 7F 0.18
BMI 27.549 ± 6 25.55 ± 5.8 0.27
Access 33AVF, 32AVG, 10ca 6AVF, 3AVG, 4ca 0.2
Years on hD 3.4 ± 2.6 5.4 ± 3.4 0.02
RA volume 47.4 ± 23.4 63.4 ± 25.2 0.03
RA fractional 
shortening
38.8 ± 9.4 28.7 ± 15.7 0.008
RV apical diameter 3.6 ± 0.7 4.0 ± 0.6 0.07
RV function 1.1 ± 0.4 1.7 ± 0.9 0.001
Annular descent 1.8 ± 0.6 1.5 ± 0.7 0.06
RV fractional 
shortening
40.5 ± 7.2 35 ± 10.9 0.07
TR severity 1.4 ± 0.7 1.9 ± 1.0 0.01
RAP 8.7 ± 3.9 12.3 ± 5.6 0.006
PAP 39.4 ± 10.5 56.9 ± 19.7 ,0.02
LVID 4.6 ± 0.6 4.6 ± 0.8 0.87
LVeF 59.1 ± 9.7 54.7 ± 14.5 0.16
PcWP 17.3 ± 6.6 23.9 ± 8.8 0.01
Abbreviations: F, female; M, male; AA, African American; c, caucasian; h, hispanic; 
AVF,  arteriovenous  fistula;  AVG,  arteriovenous  graft;  Ca,  Catheter;  BMI,  body 
mass index; hD, hemodialysis; RA, right atrial; RV, right ventricular; TR, tricuspid 
regurgitant;  RAP,  right  atrial  pressure;  PAP,  pulmonary  artery  pressure;  LVID, 
left ventricular internal dimension; LVeF, left ventricular ejection fraction; PcWP, 
pulmonary capillary wedge pressure.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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in mitral E wave velocity rather than a decrease in tissue 
Doppler E velocity. However, the potential importance of 
multifactorial diastolic dysfunction, an increasingly frequent 
cause of PH in the non-dialysis patient population, should 
not be discounted as a contributor to PH and its outcome in 
the dialysis population.
Two previous studies also suggest a causal relationship 
between PCWP and PAP. Havlucu et al followed 25   dialysis 
and 23 pre-dialysis patients for 6 months. At the end of 
6 months, left atrial diameter (LAD) (reflection of left-sided 
filling pressures), vena cava index (VCI) (reflection of RAP), 
and systolic PAP improved in the dialysis patients, whereas 
in pre-dialysis patients, VCI did not change and LAD and 
PAP actually increased. The authors concluded that effective 
HD and volume control (as reflected by decrease in LAD and 
VCI) may have resulted in improved PAP.14
In another study, Barberato et al compared dialysis 
patients with normal and pseudonormal mitral inflow   patterns, 
the latter reflecting elevated left-sided filling   pressures. Inter-
estingly, although mean LVEF was significantly lower in 
the pseudonormal group, it was still preserved on average 
(73% ± 7% versus 65% ± 10%, P , 0.01). Moreover, systolic 
PAP was significantly higher in the pseudonormal group 
(38 ± 11 mmHg versus 20 ± 6 mmHg, P = 0.01).15 These 
results further support the findings in the current study that 
elevated filling pressures in dialysis patients are associated 
with preserved LV function and elevated PAP.
In ESRD patients, even in the presence of preserved LV 
systolic function, diastolic abnormalities with impaired 
LV relaxation and increased ventricular stiffness are not 
infrequent.16–18 In our study population, 77% of the dialysis 
patients had echo evidence of abnormal diastolic function. 
Diastolic dysfunction in dialysis patients can be due to 
multiple factors. Left ventricular hypertrophy mainly as a 
result of hypertension is prevalent in dialysis patients and 
is strongly associated with impaired diastolic function. 
Furthermore, a large number of dialysis patients have dia-
betes, which by itself has been associated with increased 
myocardial stiffness and diastolic dysfunction. Other fac-
tors that may contribute to increased ventricular stiffness in 
ESRD patients include uremia and upregulation of various 
neurohormones.19
In dialysis patients, the impact of PH on clinical outcomes 
has not previously been prospectively studied. While this is 
a cross-sectional study and may have suffered from survivor 
bias, given that the mortality was higher in the patients with 
PH, the survivor bias should predispose to an underestimation 
of the frequency of PH in the US dialysis patient population. 
In a recently published retrospective database review of HD 
patients receiving echocardiograms for clinical indications, 
127 dialysis patients were evaluated, and the prevalence of 
PH was found to be 29%. Of the 37 patients with PH, 17 had 
PH at initiation of HD, and 20 patients developed PH after 
HD initiation. Survival was significantly higher in patients 
without PH. The 1-, 3-, and 5-year mortality in patients with 
and without PH were 21.4% versus 3.5%, 57.1% versus 
21.2%, and 74.8% versus 33.6% respectively.1 Similar find-
ings were noted in the current study: at 12 months follow-up, 
mortality was 26% in patients with PH and 6% in patients 
without PH. Interestingly, with respect to all-cause hospi-
talizations (including emergency room visits), no significant 
difference was found amongst the 3 groups. Thus, morbidity 
by this definition amongst dialysis patients appears to be very 
high irrespective of PAP.
In the current study, when comparing survivors with 
non-survivors, PAP and PCWP were significantly higher 
in non-survivors. On the one hand, this may reflect the 
progression of diastolic heart failure with elevated PCWP 
eventually resulting in PH, which then carries a poor long-
term prognosis. Alternatively, PH may have developed as 
a result of other causes, may not necessarily be associated 
with elevated PCWP, and may thus independently be a poor 
prognostic marker.
No relation was found between the nature of the dialysis 
access and the presence of PH. This is not unexpected. There 
is a clear rationale for aggravation of heart failure in patients 
with established PH or diastolic dysfunction due to the higher 
output imposed by a chronic graft of fistula. However, there 
is a very low likelihood that a 25%–30% increase in basal 
cardiac output over a relatively short period of time (years 
as opposed to decades) would be likely to predispose to the 
high flow induced changes in the pulmonary vascular bed 
leading to PH. The development of PH is remarkably infre-
quent (about 4%) in patients with common congenital heart 
disease such as ASD.
Limitations
We included patients in whom PAP could not be measured 
due to insufficient TR in the normal group (group 1). We did 
ensure that these patients did not have any other echocardio-
graphic signs indicating the presence of PH. Secondly, we 
used a TR jet cutoff of $2.5 m/s for the classification of PH. 
Assuming a RAP of 10 mmHg, this would equate to a PAP 
of $35 mmHg. In the setting of lower RAP, these patients may 
have been misclassified as having higher PAP. Although these 
2 scenarios may have led to misclassification by potentially International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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including PH patients in the normal group and normal patients 
in the PH group, we were still able to identify a difference in 
prognosis between the groups. Due to the small number of 
overall events, a multivariable regression analysis could not be 
performed to evaluate the extent to which PH independently 
contributed to mortality. Thus, although PH is associated with 
higher mortality, our study was not able to ascertain causality 
versus association between PH and mortality or whether PH is 
merely an indicator of sicker patients. We believe, however, 
that this approach in this cross-sectional analysis conserva-
tively provides a lower estimate of the prevalence and impact 
of PH in chronic ESRD patient on dialysis.
Conclusion
In this first prospective study of PH in US dialysis patients, 
at a single center, we found that PH is highly prevalent and 
is associated with echocardiographic evidence of elevated 
left-sided filling pressures and higher mortality. The clini-
cal importance of PH appears to be as a marker of disease 
  severity, as a potential target of therapy, and as an important 
prognostic indicator. While multiple factors may contribute 
to the development of PH in dialysis patients our results 
suggest that chronic volume overload, and/or diastolic 
dysfunction may contribute to the development of PH, 
which is associated with poorer survival. This suggests that 
the presence of PH should be incorporated in the decision 
making for renal transplantation, since PH is associated 
with worse survival, and appears to improve after renal 
transplantation.2
The results of the current study demonstrating the 
frequency and impact of PH in the US dialysis population 
underline the importance of adequate volume removal, and 
potentially the importance of future therapies targeting PH 
and diastolic dysfunction.
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